OncoMatch/Clinical Trials/NCT07134088
A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia
Is NCT07134088 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Blinatumomab for relapsed/refractory b-cell precursor acute lymphoblastic leukemia.
Treatment: Blinatumomab — The main objective of this study is to evaluate the safety and efficacy of SC blinatumomab in children below 12 years of age.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: CD19 expression (CD19+ expression)
Prior CD19-directed therapy will be allowed (with demonstrated continued CD19+ expression)
Allowed: BCR Philadelphia chromosome-positive
Any Philadelphia chromosome-positive (Ph+) participant intolerant or refractory to prior tyrosine kinase inhibitors (TKIs) are eligible
Prior therapy
Cannot have received: allogeneic hematopoietic stem cell transplant
Exception: allowed if >12 weeks before blinatumomab
Allogeneic HSCT within 12 weeks before the start of blinatumomab
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- St Jude Childrens Research Hospital · Memphis, Tennessee
- Seattle Childrens Hospital · Seattle, Washington
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify